Edition:
United States

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

23.26EUR
19 Oct 2018
Change (% chg)

€-0.16 (-0.68%)
Prev Close
€23.42
Open
€23.44
Day's High
€23.96
Day's Low
€23.20
Volume
29,313
Avg. Vol
52,901
52-wk High
€30.00
52-wk Low
€19.24

Select another date:

Thu, Aug 2 2018

BRIEF-Cellectis Operating Loss Widens To 21.7 Million US Dollars

* SAID ON WEDNESDAY ITS Q2 REVENUES WERE $5.0 MLN VS $6.5 MLN YEAR AGO

BRIEF-Cellectis Publishes Methods to Improve Clinical Use of Chimeric Antigen Receptor T-Cell Therapy

* ANNOUNCED ON TUESDAY NOVEL METHODS TO IMPROVE THE CLINICAL USE OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

BRIEF-Cellectis Announces Approval Of Amendment To Protocol For UCART123 Phase 1 Clinical Trial

* ANNOUNCED ON TUESDAY APPROVAL OF AMENDMENT TO PROTOCOL FOR PHASE 1 CLINICAL TRIAL OF UCART123 PRODUCT CANDIDATE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS

BRIEF-Cellectis Submits Investigational New Drug Application To FDA For UCART22

* SAID ON WEDNESDAY IT HAS SUBMITTED INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE US FDA REQUESTING APPROVAL TO INITIATE A PHASE 1 CLINICAL TRIAL FOR UCART22

BRIEF-Cellectis Partners With Harvard’S Wyss Institute For Research On Human Genome

* SAID ON TUESDAY THAT HARVARD’S WYSS INSTITUTE PARTNERS WITH CELLECTIS TO RECODE HUMAN GENOME

Select another date: